OTC: GCAN

Green
C was the owner of an exclusive, worldwide license for an eluting transmucosal patch platform (“ETP”) for non-invasive drug
delivery in the cannabis field as further described in the exclusive license agreement dated June 21, 2018 with Pharmedica Ltd. (see
Note J).

After
the consummation of the above-described transactions, the Company switched its business model in fiscal 2018 and no longer intended to
pursue E-commerce, advertising, licensing (except as specified below) or direct investment operations. Instead, the Company is now engaged
in the development and commercialization of innovative cannabinoid therapeutics.

From
July 2018 through mid-2021, the Company focused on commercializing its own and licensed technologies worldwide for transmucosal and transdermal
delivery of legal medical or recreational cannabis (other than in the field of oral care) and cannabinoids. The Company’s initial
product was an oral transmucosal patch platform which for provides for loaded actives to be absorbed by the buccal mucosa into the body.
Although the Company was able to launch the product and received some limited initial orders, the Company’s management ultimately
elected to pursue other opportunities which they believed offered the Company greater potential for growth and ultimate profitability.

Accordingly,
on October 19, 2021 the Company entered into a license agreement with Shaare Zedek Scientific Ltd. (“SZS”), the technology
transfer arm of Jerusalem’s Shaare Zedek Medical Center (SZMC). The license agreement covers the license of SZS’s novel cannabinoid
therapeutic focused on treatment of autism, schizophrenia, Parkinson’s disease, Alzheimer’s disease and other neuropsychiatric
disorders.

Accompanying
the license agreement is a joint research and development agreement, which will focus on continuing the clinical program spearheaded
by Dr. Adi Aran, M.D. Director of Pediatric Neurology at SZMC, Board Member of the Israeli Society for Pediatric Neurology, and co-inventor
of the novel cannabinoid therapy.

The
licensing agreement requires the Company to pay $5,000 per year beginning on the third year from the Effective Date, which was June 21,
2021. The licensing fee is increased every two calendar years by an additional $5,000 up to a maximum of $30,000. Additionally, there
are milestone payments of $75,000 upon initiation of the Phase 2 Clinical Trial, $200,000 from the initiation of a Phase 3 Clinical Trial,
and $300,000 upon receipt of the first regulatory approval for a drug product. The licensing fees are due 30 days from the beginning
of each calendar year. The developmental milestone payments are due 60 days from the date that the milestone has been achieved. At this
time the Company is waiting for the Principal Investigator (PI) to source the specialized active pharmaceutical ingredients (API) required
to facilitate the Phase 2 Clinical Trial, and as such the annual licensing fee payments have been put on hold. It is not known when the
specialized and proprietary API will be able to be sourced. The royalties for dietary supplement sales are 2.25% for net sales between
$1-$10 million, 2.5% for net sales between $10 million and $50 million, and 3% for net sales between $50 million and $100 million. Royalty
payments for dietary products are capped at $100 million in net sales. Royalties for drug products are 1% for net sales between $1 and
$100 million, 1.5% for net sales between $100 million and $500 million, and 2% for net sales greater than $500 million. There is a sublicense
royalty of 12%. The Company has concluded the preclinical studies as was communicated in a press release issued by the Company on February
27, 2024. The Company received approval from the Israel Ministry of Health to proceed with a Phase II Clinical Trial as communicated
by the Company in a press release on July 5, 2023. The Company is now waiting for the PI to source the API needed for the clinical trial.
In order to proceed with the Clinical Trial the Company will need to raise additional funds to finance the cost of the Phase II Clinical
Trial. The Clinical Trial is expected to take between 18 and 24 months from the start date to complete. The regulatory approval timeline
is uncertain at this time as the Company is awaiting clinical data from the Phase II Clinical Trial in order to submit an application
to the FDA to begin the regulatory process.

Reverse
Stock Split and Series B Preferred Shares: The Company filed an amendment to its Certificate of Incorporation with the Secretary
of State of Florida to effectuate a 1-for-1,500 reverse stock split of its Common Stock (the “Reverse Split”) effective October
16, 2025. Share, equity award, and per share amounts contained in the consolidated financial statements have been adjusted to reflect
the Reverse Stock Splits for all prior periods presented. (See Note-J)

This
Information Statement (the “Information Statement”) has been filed with the Securities and Exchange Commission and
is being furnished, pursuant to Section 14C of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
to the holders of common stock, par value $.001 per share (the “Common Stock”), of The Greater Cannabis Company, Inc.,
a Florida corporation (the “Company”), to notify shareholders that on or about April 4, 2025, the Company received
written consents in lieu of a meeting from (a) the sole director of the Company; and (b) holders of shares of voting stock of the Company
representing approximately 50.3% of total voting power of the issued and outstanding shares of voting stock of the Company (the “Majority
Shareholders”), authorizing the Company to amend its Articles of Incorporation to:

●
to
effectuate a reverse stock split of the Company’s issued outstanding shares of common stock in a ratio of one-for-1,500; and

●
create
a new class of 1,000 shares of preferred stock, $.001 per share, designated as Series B Convertible Preferred Stock

2

The
reverse stock split, will become effective upon filing of an amendment to our Articles of Incorporation with the Florida Secretary of
State, a copy of which is included as Exhibit 33.1 in this Quarterly Report (the “Reverse Stock Split Amendment”).
The amendment creating the Series B Preferred Shares, a copy of which is attached as Exhibit 34.1 to this Information Statement (the
“Series B Amendment”), will only be filed with the Florida Secretary of State after the filing of the Reverse Stock
Split Amendment.

Competition

There
are a number of other companies operating in the cannabis space. Such companies range from producers of cannabis plants to makers of
cannabis-based edible products to developers of different methods of cannabis delivery. Known competitors in our space include Jazz Pharmaceuticals
(NASDAQ: JAZZ) and Zynerba Pharmaceuticals (NASDAQ: ZYNE).

Intellectual
Property

Not
applicable.

Costs
and Effects of Complying with Environmental Regulations

Not
applicable.

Research
and Development

The
Company is involved in additional research and development of innovative cannabinoid based therapeutics. The Company expects to develop
new formulations around cannabinoid therapeutics and intends to file more patents to protect the intellectual property resulting from
that R&D. To support these efforts, the Company will allocate additional funds of approximately $250,000 from financing proceeds
to research and development, sample productions and preclinical studies.

Government
Regulation

Cannabis
is currently a Schedule I controlled substance under the Controlled Substances Act (“CSA”) and is, therefore, illegal under
federal law. Even in those states in which the use of cannabis has been legalized pursuant to state law, its use, possession or cultivation
remains a violation of federal law. A Schedule I controlled substance is defined as one that has no currently accepted medical use in
the United States, a lack of safety for use under medical supervision and a high potential for abuse. The U.S. Department of Justice
(the “DOJ”) defines Schedule I controlled substances as “the most dangerous drugs of all the drug schedules with potentially
severe psychological or physical dependence.” If the federal government decides to enforce the CSA in Colorado with respect to
cannabis, persons that are charged with distributing, possessing with intent to distribute or growing cannabis could be subject to fines
and/or terms of imprisonment, the maximum being life imprisonment and a $50 million fine.

Notwithstanding
the CSA, as of the date of this filing, 33 U.S. states, the District of Columbia and the U.S. territories of Guam and Puerto Rico allow
their residents to use medical cannabis and 11 states have legalized recreational marijuana. Such state and territorial laws are in conflict
with the federal CSA, which makes cannabis use and possession illegal at the federal level.

In
light of such conflict between federal laws and state laws regarding cannabis, the previous administration under President Obama had
effectively stated that it was not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully
abiding by state-designated laws allowing the use and distribution of medical cannabis. For example, the prior DOJ Deputy Attorney General
of the Obama administration, James M. Cole, issued a memorandum (the “Cole Memo”) to all United States Attorneys providing
updated guidance to federal prosecutors concerning cannabis enforcement under the CSA (see “-The Cole Memo”). In addition,
the Financial Crimes Enforcement Network (“FinCEN”) provided guidelines (the “FinCEN Guidelines”) on February
14, 2014, regarding how financial institutions can provide services to cannabis-related businesses consistent with their Bank Secrecy
Act obligations).

3

Cole
Memo

Because
of the discrepancy between the laws in some states, which permit the distribution and sale of medical and recreational cannabis, from
federal law that prohibits any such activities, DOJ Deputy Attorney General James M. Cole issued the Cole Memo concerning cannabis enforcement
under the CSA. The Cole Memo guidance applies to all of the DOJ’s federal enforcement activity, including civil enforcement and
criminal investigations and prosecutions, concerning cannabis in all states.

The
Cole Memo reiterates Congress’s determination that cannabis is a dangerous drug and that the illegal distribution and sale of cannabis
is a serious crime that provides a significant source of revenue to large-scale criminal enterprises, gangs, and cartels. The Cole Memo
notes that the DOJ is committed to enforcement of the CSA consistent with those determinations. It also notes that the DOJ is committed
to using its investigative and prosecutorial resources to address the most significant threats in the most effective, consistent, and
rational way. In furtherance of those objectives, the Cole Memo provides guidance to DOJ attorneys and law enforcement to focus their
enforcement resources on persons or organizations whose conduct interferes with any one or more of the following important priorities
(the “Enforcement Priorities”) in preventing:

●
the
distribution of cannabis to minors;

●
revenue
from the sale of cannabis from going to criminal enterprises, gangs, and cartels;

●
the
diversion of cannabis from states where it is legal under state law in some form to other states;

●
state-authorized
cannabis activity from being used as a cover or pretext for the trafficking of other illegal drugs or other illegal activity;

●
violence
and the use of firearms in the cultivation and distribution of cannabis;

●
drugged
driving and the exacerbation of other adverse public health consequences associated with cannabis use;

●
the
growing of cannabis on public lands and the attendant public safety and environmental dangers posed by cannabis production on public
lands; and

●
cannabis
possession or use on federal property.

4

We
intend to conduct rigorous due diligence to verify the legality of all activities that we engage in and ensure that our activities do
not interfere with any of the Enforcement Priorities set forth in the Cole Memo.

The
Cole Memo is meant only as a guide for United States Attorneys and does not alter in any way the Department of Justice’s authority
to enforce Federal law, including Federal laws relating to cannabis, regardless of state law.

Agriculture
Improvement Act of 2018

The
federal Agricultural Improvement Act of 2018, signed into law on December 20, 2018, along with the Agricultural Act of 2014, the corresponding
Consolidated Appropriations Act of 2016 provisions (as extended by resolution into 2018) and related state law, provide for the cultivation,
processing, manufacturing and sale of hemp-derived products, as part of agricultural pilot programs and/or state plans adopted by individual
states, including Colorado. However, there can be no assurance that new legislation or regulations may be introduced at either the federal
and/or state level which, if passed, would impose substantial new regulatory requirements on the manufacture, packaging, labeling, advertising
and distribution and sale of hemp-derived products. New legislation or regulations may require the reformulation, elimination or relabeling
of certain products to meet new standards and revisions to certain sales and marketing materials and it is possible that the costs of
complying with these new regulatory requirements could be material.

FDA

The
use of our technology may be subject to pre-approval by the FDA for certain applications, or equivalent regulatory body approval in other
jurisdictions. If so, obtaining FDA and other approvals will require a substantial investment of funds and may take years. In such case,
we intend to rely on our sublicensees or strategic partners to fund and undertake any required approval process. There is no assurance
that we will be able to successfully obtain any such required regulatory approvals needed to enter certain markets or market our technology
for certain applications.

We
also may be required to comply with FDA and other federal, state and foreign regulations regarding safety, dosing and other similar matters.

Employees

We
have one person providing us services on a full-time basis, our chief executive officer.